2005
μ-Calpain Regulates Receptor Activator of NF-κB Ligand (RANKL)-supported Osteoclastogenesis via NF-κB Activation in RAW 264.7 Cells*
Lee FY, Kim DW, Karmin JA, Hong D, Chang SS, Fujisawa M, Takayanagi H, Bigliani LU, Blaine TA, Lee HJ. μ-Calpain Regulates Receptor Activator of NF-κB Ligand (RANKL)-supported Osteoclastogenesis via NF-κB Activation in RAW 264.7 Cells*. Journal Of Biological Chemistry 2005, 280: 29929-29936. PMID: 15955824, DOI: 10.1074/jbc.m414600200.Peer-Reviewed Original ResearchConceptsRAW 264.7 cellsNF-kappaB activationReceptor activatorCalpain inhibitorsCell-permeable calpain inhibitorMatrix metalloproteinase-9Regulation of RANKLNF-κB activationNF-κB ligandNF-kappaB ligandMonocyte/macrophage progenitorsRole of calpainMurine RAW 264.7 cellsCell typesMetalloproteinase-9Osteoclastogenic markersCalpain activationResistant acidDecreased expressionOsteoclastogenesisRANKLCalpain activityMu-calpainInhibitorsActivation
2004
Bisphosphonates May Reduce Recurrence in Giant Cell Tumor by Inducing Apoptosis
Chang SS, Suratwala SJ, Jung KM, Doppelt JD, Zhang HZ, Blaine TA, Kim TW, Winchester RJ, Lee FY. Bisphosphonates May Reduce Recurrence in Giant Cell Tumor by Inducing Apoptosis. Clinical Orthopaedics And Related Research® 2004, 426: 103-109. PMID: 15346059, DOI: 10.1097/01.blo.0000141372.54456.80.Peer-Reviewed Original ResearchConceptsGiant cell tumorCell tumorsAdjuvant therapyGiant cellsExogenous receptor activatorSpecific adjuvant therapyExtensive bone destructionTumor culturesLocal adjuvant therapyHigh recurrence rateNovel adjuvant therapyOsteoclastlike giant cellsNovel therapeutic agentsNF-kappaB ligandDose-dependent mannerBone destructionRecurrence rateAggressive tumorsBone resorptionSystemic useReceptor activatorAutocrine loopAutocrine mannerTumorsAutocrine regulation